AU - Busse, William W. AU - Kraft, Monica AU - Rabe, Klaus F. AU - Deniz, Yamo AU - Rowe, Paul J. AU - Ruddy, Marcella AU - Castro，马里奥TI -理解的关键问题不受控制的持续哮喘的治疗2型炎症援助- 10.1183/13993003.03393 -2020 DP - 2021年8月01 TA -欧洲呼吸杂志》第六PG - 2003393 - 58 //www.qdcxjkg.com/content/58/2/2003393.short的IP - 2 4099 - 4100 //www.qdcxjkg.com/content/58/2/2003393.fullSO - Eur Respir J2021 Aug 01;58 AB -哮喘是一种复杂的呼吸系统疾病，其严重程度和治疗反应各不相同。几种具有独特临床和炎症特征的哮喘表型已经被确定。基于不同分子谱的内型有助于进一步阐明哮喘的异质性。2型炎症,包括先天(2型先天淋巴细胞)和自适应(辅助2型细胞)的免疫系统,支撑在哮喘、慢性炎症的复杂病理生理学以及共病的疾病(如慢性鼻窦炎和鼻息肉,过敏性鼻炎和过敏性皮炎)。2型炎症的特征是2型细胞因子白细胞介素(IL)-4、IL-5和IL-13的上调，ige介导的免疫介质释放和上皮或表皮屏障功能障碍。靶向这些关键的近端2型细胞因子在最近的研究中显示出了疗效，这些研究采用了个性化的方法使用靶向生物制剂进行治疗。2型细胞因子下游的生物标志物水平升高，包括部分呼出一氧化氮、血清IgE、血液和痰中嗜酸性粒细胞，与2型炎症的机制有关。 They have the potential to aid diagnosis, and to predict and monitor response to treatment. The objective of this review is to summarise the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.This review covers the pathophysiology of type 2 inflammation in asthma, its influence on type 2 comorbidities, and ways in which type 2 biomarkers can be harnessed to improve diagnosis and further personalise treatments in the age of biologic medicines https://bit.ly/2MSOI2O